Update on the prevention and treatment of neonatal Carbapenem-resistant Klebsiella pneumoniae
10.3760/cma.j.issn.1673-4912.2023.04.013
- VernacularTitle:新生儿耐碳青霉烯类肺炎克雷伯菌感染的防治进展
- Author:
Xinru WANG
1
;
Yongyan SHI
Author Information
1. 中国医科大学附属盛京医院儿内科，沈阳 110004
- Keywords:
Neonate;
Carbapenem-resistant Klebsiella pneumoniae;
Treatment;
Prevention
- From:
Chinese Pediatric Emergency Medicine
2023;30(4):302-306
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the use of broad-spectrum antibiotics in clinical practice has led to an increase in the detection of Carbapenem-resistant Klebsiella pneumoniae(CrKP)in neonatal intensive care units.CrKP infection in newborns usually lacks specific clinical manifestations and can lead to bacteremia, meningitis and abdominal infections, which can be life-threatening.Combination of carbapenem antibiotics or newer drugs such as ceftazidime/avibactam, tigecycline and polymyxin are currently effective treatment options for CrKP infection in neonates.In addition to rational drug use, strict antimicrobial stewardship, hospital infection prevention and control measures are needed to reduce the colonisation and spread of CrKP in the neonatal ward.
